Total number of additional common shares of an entity that have been sold or granted to shareholders.

No definition available.

Name:	nnvc_AdditionalCommonStockSharesIssued
Namespace Prefix:	nnvc_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Total number of additional nonredeemable preferred shares issued to shareholders.

+ References

No definition available.

+ Details

Name:	nnvc_AdditionalPreferredStockSharesIssued
Namespace Prefix:	nnvc_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Amount of annual base salary as agreed to be paid by the company under the employment agreement.

+ References

No definition available.

+ Details

Name:	nnvc_BaseSalary
Namespace Prefix:	nnvc_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- References

No definition available.

+ Details

Name:	nnvc_CommitmentsAndContingenciesLineItems
Namespace Prefix:	nnvc_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Date the employment agreement was made.

+ References

No definition available.

+ Details

Name:	nnvc_EmploymentAgreementTerm
Namespace Prefix:	nnvc_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

This element represents the certain amount of estimated salary increase in their base.

+ References

No definition available.

+ Details

Name:	nnvc_IncreaseInBaseSalary
Namespace Prefix:	nnvc_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Royalty expense calculated as a percentage of net sales.

+ References

No definition available.

+ Details

Name:	nnvc_PercentageOfNetSalesAllocatedForRoyaltyPayments
Namespace Prefix:	nnvc_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

It represents the amount of stock issued during period, value, new issues, cash upon completion of phase I clinical trials.

+ References

No definition available.

+ Details

Name:	nnvc_StockIssuedDuringPeriodValueNewIssuesCashUponCompletionOfPhase1ClinicalTrials
Namespace Prefix:	nnvc_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

It represents the amount of stock issued during period, value, new issues, cash upon completion of phase II clinical trials.

+ References

No definition available.

+ Details

Name:	nnvc_StockIssuedDuringPeriodValueNewIssuesCashUponCompletionOfPhase2ClinicalTrials
Namespace Prefix:	nnvc_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

It represents the amount of stock issued during period, value, new issues, cash upon completion of phase III clinical trials.

+ References

No definition available.

+ Details

Name:	nnvc_StockIssuedDuringPeriodValueNewIssuesCashUponCompletionOfPhase3ClinicalTrials
Namespace Prefix:	nnvc_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

+ Details

Name:	us-gaap_CommonStockSharesIssued
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

The maximum number of shares authorized for issuance under the deferred compensation arrangement as of the balance sheet date.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901

+ Details

Name:	us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.

+ References

+ Details

Name:	us-gaap_PreferredStockSharesIssued
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Amount of noncash expense for share-based payment arrangement.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

+ Details

Name:	us-gaap_ShareBasedCompensation
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Number of options vested.

+ References

No definition available.

+ Details

Name:	us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of new stock issued during the period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

+ Details

Name:	us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nnvc_TheracourPharmaIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_TitleOfIndividualAxis=nnvc_PresidentAndBoardOfDirectorsChairmanMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_TitleOfIndividualAxis=nnvc_ChiefScientificOfficerMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_TitleOfIndividualAxis=srt_VicePresidentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=nnvc_MrTaraporewalaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Commitments and Contingencies (Details) - USD ($)					3 Months Ended
Commitments and Contingencies (Details) - USD ($)	Nov. 01, 2019	Jan. 01, 2015	May 30, 2013	Mar. 03, 2010	Sep. 30, 2020	Sep. 30, 2019	Jun. 30, 2020
Commitments and Contingencies [Line Items]
Common stock, shares issued					10,665,931		9,083,414
Employment Agreement Term					3 years
Cash upon completion of Phase I Clinical Trials	$ 1,500,000
Cash upon completion of Phase II Clinical Trials	2,500,000
Cash upon completion of Phase III Clinical Trials	$ 5,000,000
TheraCour
Commitments and Contingencies [Line Items]
Stock Issued During Period, Shares, New Issues	75,000
Cash upon completion of Phase I Clinical Trials	$ 1,500,000
Cash upon completion of Phase II Clinical Trials	2,500,000
Cash upon completion of Phase III Clinical Trials	$ 5,000,000
Percentage of Net Sales Allocated for Royalty Payments	15.00%				15.00%
Series A Preferred stock
Commitments and Contingencies [Line Items]
Share-based Compensation					$ 45,654	$ 47,260
President And Board Of Directors, Chairman [Member]
Commitments and Contingencies [Line Items]
Base Salary					$ 400,000
Deferred Compensation Arrangement with Individual, Shares Authorized for Issuance					26,250
President And Board Of Directors, Chairman [Member] \| Share-based Compensation Award, Tranche One [Member]
Commitments and Contingencies [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares					8,750
President And Board Of Directors, Chairman [Member] \| Share-based Compensation Award, Tranche Two [Member]
Commitments and Contingencies [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares					8,750
President And Board Of Directors, Chairman [Member] \| Share-based Compensation Award, Tranche Three [Member]
Commitments and Contingencies [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares					8,750
Chief Scientific Officer [Member]
Commitments and Contingencies [Line Items]
Common stock, shares issued				1,786
Additional Common Stock Shares Issued				1,786
Increase In Base Salary				$ 150,000
Employment Agreement Term				4 years
Vice President [Member]
Commitments and Contingencies [Line Items]
Common stock, shares issued				1,786
Additional Common Stock Shares Issued				1,786
Preferred stock, shares issued				1,340
Additional Preferred Stock Shares Issued				1,340
Increase In Base Salary				$ 150,000
Employment Agreement Term				4 years
Chief Financial Officer [Member]
Commitments and Contingencies [Line Items]
Increase In Base Salary		$ 10,800	$ 9,000
Employment Agreement Term			3 years
Chief Financial Officer [Member] \| Series A Preferred stock
Commitments and Contingencies [Line Items]
Preferred stock, shares issued			129
Mr Taraporewala [Member]
Commitments and Contingencies [Line Items]
Percentage of Net Sales Allocated for Royalty Payments	15.00%